Lamivudine/Zidovudine Mylan

Lamivudine and Zidovudine, the active ingredients in Lamivudine/Zidovudine Mylan, are nucleoside reverse transcriptase inhibitors presented as oral tablets (strength unspecified) for oral use. These agents are part of combination regimens that are standard of care for managing chronic HIV infection.

GNH USA supplies Lamivudine/Zidovudine Mylan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our network ensures reliable delivery and regulatory compliance across multiple regions.

Lamivudine/Zidovudine is a nucleoside reverse transcriptase inhibitor used in the management of HIV infection. - HIV-1 infection (adults): reduces viral replication, improves CD4+ T‑cell counts, and delays disease progression when used as part of combination antiretroviral therapy. - HIV-1 infection (children): forms part of combination antiretroviral therapy to control viral load and support immune development in pediatric patients. - HIV-1 infection (pregnant women): used with other agents to lower the risk of mother‑to‑child transmission while maintaining maternal health.

Lamivudine/Zidovudine may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient cranial discomfort. - Fatigue: general tiredness or weakness. - Diarrhea: loose stools, usually self‑limiting.

Serious or Rare Side Effects: - Lactic acidosis: severe metabolic disturbance requiring immediate medical attention. - Hepatic steatosis: accumulation of fat in the liver that can progress to liver failure. - Bone marrow suppression: anemia, neutropenia, or thrombocytopenia. - Hypersensitivity reactions: rash, fever, or Stevens‑Johnson syndrome.

Before initiating Lamivudine/Zidovudine therapy, clinicians should consider several precautionary measures to ensure patient safety. - Monitor blood counts: perform baseline and periodic CBC to detect anemia or neutropenia. - Assess liver function: check transaminases regularly due to risk of hepatic toxicity. - Evaluate hypersensitivity: discontinue if rash, fever, or severe skin reactions develop. - Adjust for renal impairment: dose may need modification in patients with reduced kidney function. - Store at ambient temperature below 25°C: keep in original packaging, protect from moisture and direct sunlight.

Lamivudine/Zidovudine can interact with other medicines, affecting efficacy or toxicity.

Major Interactions (Avoid): - Didanosine: concurrent use increases risk of pancreatitis; avoid co‑administration. - Stavudine: combined therapy heightens mitochondrial toxicity; avoid together. - Alcohol: may exacerbate hepatic side effects and lactic acidosis; avoid.

Moderate Interactions (Monitor Closely): - Efavirenz: may raise zidovudine plasma concentrations; monitor therapeutic levels. - Ritonavir‑boosted protease inhibitors: can alter zidovudine metabolism; adjust dose if needed. - Nephrotoxic agents: concurrent use may worsen renal function; monitor kidney parameters.